A phase 2 study of inotuzumab ozogamicin in patients with indolent B-cell non-Hodgkin lymphoma refractory to rituximab alone, rituximab and chemotherapy, or radioimmunotherapy

British Journal of Haematology

Volumn 174, Issue 4, 2016, Pages 571-581

  Goy, Andre ^a   Forero, Andres ^b   Wagner Johnston, Nina ^c   Christopher Ehmann, W ^d   Tsai, Michaela ^e   Hatake, Kiyohiko ^f   Ananthakrishnan, Revathi ^g,h   Volkert, Angela ^h,k   Vandendries, Erik ^h   Ogura, Michinori ^i,j  

^a HUMC   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d PENN STATE CANCER INSTITUTE   (United States)

^e Minnesota Oncology ^*  (United States)

^f CANCER INSTITUTE HOSPITAL   (Japan)

^g SYNEOS HEALTH   (United States)

^h PFIZER INC   (United States)

ⁱ NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

^j Tokai Central Hospital of Japan Mutual Aid Association of Public School Teachers   (Japan)

^k Infinity Pharmaceuticals Inc   (United States)

more..

Author keywords

chemotherapy; inotuzumab ozogamicin; non Hodgkin lymphoma; radioimmunotherapy; rituximab

Indexed keywords

ASPARTATE AMINOTRANSFERASE; GAMMA GLUTAMYLTRANSFERASE; INOTUZUMAB OZOGAMICIN; RITUXIMAB;

ABDOMINAL PAIN; ADULT; ANEMIA; ARTHRALGIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HEADACHE; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOPHOSPHATEMIA; LARGE CELL LYMPHOMA; LEUKOPENIA; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIOIMMUNOTHERAPY; RASH; SEPSIS; SIDE EFFECT; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

EID: 84982957771     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.14094     Document Type: Article

References (39)

1. Advani, A., Coiffier, B., Czuczman, M.S., Dreyling, M., Foran, J., Gine, E., Gisselbrecht, C., Ketterer, N., Nasta, S., Rohatiner, A., Schmidt-Wolf, I.G., Schuler, M., Sierra, J., Smith, M.R., Verhoef, G., Winter, J.N., Boni, J., Vandendries, E., Shapiro, M. & Fayad, L. (2010) Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. Journal of Clinical Oncology, 28, 2085–2093.
2. Advani, A.S., Stein, A.S., Kantarjian, H.M., Shustov, A.R., DeAngelo, D.J., Ananthakrishnan, R., Liau, K., Vandendries, E. & Stock, W. (2014) A phase II study of weekly inotuzumab ozogamicin (InO) in adult patients with CD22-positive acute lymphoblastic leukemia (ALL) in second or later salvage. Blood, 124, 2255–2255.
3. Cesano, A., Gayko, U., Brannan, C., Kapushoc, H., Fields, S.Z. & Perkins, S.L. (2002) Differential expression of CD22 in indolent and aggressive non-Hodgkin's lymphoma (NHL): implications for targeted therapy. Blood, 100 (suppl), 350a, abstract 1358.
4. Cheson, B.D. (1998) Current approaches to therapy for indolent non-Hodgkin's lymphoma. Oncology (Williston Park), 12, 25–34.
5. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244.
6. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V.; International Harmonization Project on Lymphoma. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579–586.
7. Czuczman, M.S., Kahanic, S., Forero, A., Davis, G., Munteanu, M., Van Den Neste, E., Offner, F., Bron, D., Quick, D. & Fowler, N. (2015) Results of a phase II study of bendamustine and ofatumumab in untreated indolent B cell non-Hodgkin's lymphoma. Annals of Hematology, 94, 633–641.
8. DiJoseph, J.F., Armellino, D.C., Boghaert, E.R., Khandke, K., Dougher, M.M., Sridharan, L., Kunz, A., Hamann, P.R., Gorovits, B., Udata, C., Moran, J.K., Popplewell, A.G., Stephens, S., Frost, P. & Damle, N.K. (2004) Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood, 103, 1807–1814.
9. Fayad, L., Offner, F., Smith, M.R., Verhoef, G., Johnson, P., Kaufman, J.L., Rohatiner, A., Advani, A., Foran, J., Hess, G., Coiffier, B., Czuczman, M., Gine, E., Durrant, S., Kneissl, M., Luu, K.T., Hua, S.Y., Boni, J., Vandendries, E. & Dang, N.H. (2013) Safety and clinical activity of a combination therapy comprising two antibody-based targeting agents for the treatment of non-Hodgkin lymphoma: results of a phase I/II study evaluating the immunoconjugate inotuzumab ozogamicin with rituximab. Journal of Clinical Oncology, 31, 573–583.
10. Fisher, R.I., LeBlanc, M., Press, O.W., Maloney, D.G., Unger, J.M. & Miller, T.P. (2005) New treatment options have changed the survival of patients with follicular lymphoma. Journal of Clinical Oncology, 23, 8447–8452.
11. Friedberg, J.W., Cohen, P., Chen, L., Robinson, K.S., Forero-Torres, A., La Casce, A.S., Fayad, L.E., Bessudo, A., Camacho, E.S., Williams, M.E., van der Jagt, R.H., Oliver, J.W. & Cheson, B.D. (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. Journal of Clinical Oncology, 26, 204–210.
12. Gopal, A.K., Kahl, B.S., de Vos, S., Wagner-Johnston, N.D., Schuster, S.J., Jurczak, W.J., Flinn, I.W., Flowers, C.R., Martin, P., Viardot, A., Blum, K.A., Goy, A.H., Davies, A.J., Zinzani, P.L., Dreyling, M., Johnson, D., Miller, L.L., Holes, L., Li, D., Dansey, R.D., Godfrey, W.R. & Salles, G.A. (2014) PI3Kdelta inhibition by idelalisib in patients with relapsed indolent lymphoma. New England Journal of Medicine, 370, 1008–1018.
13. Hainsworth, J.D., Litchy, S., Burris, H.A. III, Scullin, D.C. Jr, Corso, S.W., Yardley, D.A., Morrissey, L. & Greco, F.A. (2002) Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. Journal of Clinical Oncology, 20, 4261–4267.
14. Halwani, A.S. & Link, B.K. (2011) Chemotherapy and antibody combinations for relapsed/refractory non-Hodgkin's lymphoma. Expert Review of Anticancer Therapy, 11, 443–455.
15. Hanna, R., Ong, G.L. & Mattes, M.J. (1996) Processing of antibodies bound to B-cell lymphomas and other hematological malignancies. Cancer Research, 56, 3062–3068.
16. Jabbour, E., O'Brien, S., Huang, X., Thomas, D., Rytting, M., Sasaki, K., Cortes, J., Garcia-Manero, G., Kadia, T., Ravandi, F., Pierce, S. & Kantarjian, H. (2015) Prognostic factors for outcome in patients with refractory and relapsed acute lymphocytic leukemia treated with inotuzumab ozogamicin, a CD22 monoclonal antibody. American Journal of Hematology, 90, 193–196.
17. Kahl, B.S., Bartlett, N.L., Leonard, J.P., Chen, L., Ganjoo, K., Williams, M.E., Czuczman, M.S., Robinson, K.S., Joyce, R., van der Jagt, R.H. & Cheson, B.D. (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a multicenter study. Cancer, 116, 106–114.
18. Keating, G.M. (2010) Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs, 70, 1445–1476.
19. Kirschbaum, M., Frankel, P., Popplewell, L., Zain, J., Delioukina, M., Pullarkat, V., Matsuoka, D., Pulone, B., Rotter, A.J., Espinoza-Delgado, I., Nademanee, A., Forman, S.J., Gandara, D. & Newman, E. (2011) Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. Journal of Clinical Oncology, 29, 1198–1203.
20. Leonard, J.P., Coleman, M., Ketas, J.C., Chadburn, A., Furman, R., Schuster, M.W., Feldman, E.J., Ashe, M., Schuster, S.J., Wegener, W.A., Hansen, H.J., Ziccardi, H., Eschenberg, M., Gayko, U., Fields, S.Z., Cesano, A. & Goldenberg, D.M. (2004) Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clinical Cancer Research, 10, 5327–5334.
21. Maloney, D., Morschhauser, F., Linden, O., Hagenbeek, A. & Gisselbrecht, C. (2010) Diversity in antibody-based approaches to non-Hodgkin lymphoma. Leukemia and Lymphoma, 51(suppl 1), 20–27.
22. McLaughlin, P., Grillo-Lopez, A.J., Link, B.K., Levy, R., Czuczman, M.S., Williams, M.E., Heyman, M.R., Bence-Bruckler, I., White, C.A., Cabanillas, F., Jain, V., Ho, A.D., Lister, J., Wey, K., Shen, D. & Dallaire, B.K. (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Journal of Clinical Oncology, 16, 2825–2833.
23. Ogura, M., Tobinai, K., Hatake, K., Uchida, T., Kasai, M., Oyama, T., Suzuki, T., Kobayashi, Y., Watanabe, T., Azuma, T., Mori, M., Terui, Y., Yokoyama, M., Mishima, Y., Takahashi, S., Ono, C. & Ohata, J. (2010) Phase I study of inotuzumab ozogamicin (CMC-544) in Japanese patients with follicular lymphoma pretreated with rituximab-based therapy. Cancer Science, 101, 1840–1845.
24. Ogura, M., Hatake, K., Ando, K., Tobinai, K., Tokushige, K., Ono, C., Ishibashi, T. & Vandendries, E. (2012) Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/refractory B-cell non-Hodgkin lymphoma. Cancer Science, 103, 933–938.
25. O'Reilly, M.K., Tian, H. & Paulson, J.C. (2011) CD22 is a recycling receptor that can shuttle cargo between the cell surface and endosomal compartments of B cells. Journal of Immunology, 186, 1554–1563.
26. Rezvani, A.R. & Maloney, D.G. (2011) Rituximab resistance. Best Practice and Research. Clinical Haematology, 24, 203–216.
27. Salles, G., Seymour, J.F., Offner, F., Lopez-Guillermo, A., Belada, D., Xerri, L., Feugier, P., Bouabdallah, R., Catalano, J.V., Brice, P., Caballero, D., Haioun, C., Pedersen, L.M., Delmer, A., Simpson, D., Leppa, S., Soubeyran, P., Hagenbeek, A., Casasnovas, O., Intragumtornchai, T., Ferme, C., da Silva, M.G., Sebban, C., Lister, A., Estell, J.A., Milone, G., Sonet, A., Mendila, M., Coiffier, B. & Tilly, H. (2011) Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet, 377, 42–51.
28. Sehn, L.H., Goy, A., Offner, F.C., Martinelli, G., Caballero, M.D., Gadeberg, O., Baetz, T., Zelenetz, A.D., Gaidano, G., Fayad, L.E., Buckstein, R., Friedberg, J.W., Crump, M., Jaksic, B., Zinzani, P.L., Padmanabhan Iyer, S., Sahin, D., Chai, A., Fingerle-Rowson, G. & Press, O.W. (2015) Randomized phase II trial comparing obinutuzumab (GA101) with rituximab in patients with relapsed CD20+ indolent B-cell non-Hodgkin lymphoma: final analysis of the GAUSS study. Journal of Clinical Oncology, 33, 3467–3474.
29. Shan, D. & Press, O.W. (1995) Constitutive endocytosis and degradation of CD22 by human B cells. Journal of Immunology, 154, 4466–4475.
30. Shor, B., Gerber, H.P. & Sapra, P. (2014) Preclinical and clinical development of inotuzumab-ozogamicin in hematological malignancies. Molecular Immunology, 67, 107–116.
31. Siegel, R.L., Miller, K.D. & Jemal, A. (2015) Cancer statistics, 2015. CA: A Cancer Journal for Clinicians, 65, 5–29.
32. Stathis, A. & Ghielmini, M. (2012) New agents for the treatment of lymphoma. Annals of Oncology, 23 (suppl 10), x92–x98.
33. Suresh, T., Lee, L.X., Joshi, J. & Barta, S.K. (2014) New antibody approaches to lymphoma therapy. Journal of Hematology and Oncology, 7, 58.
34. Tan, D. & Horning, S.J. (2008) Follicular lymphoma: clinical features and treatment. Hematology/Oncology Clinics of North America, 22, 863–882, viii.
35. Tan, D., Horning, S.J., Hoppe, R.T., Levy, R., Rosenberg, S.A., Sigal, B.M., Warnke, R.A., Natkunam, Y., Han, S.S., Yuen, A., Plevritis, S.K. & Advani, R.H. (2013) Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience. Blood, 122, 981–987.
36. The Non-Hodgkin's Lymphoma Classification Project (1997) A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood, 89, 3909–3918.
37. Tomblyn, M. (2012) Radioimmunotherapy for B-cell non-Hodgkin lymphomas. Cancer Control, 19, 196–203.
38. Witzig, T.E., Wiernik, P.H., Moore, T., Reeder, C., Cole, C., Justice, G., Kaplan, H., Voralia, M., Pietronigro, D., Takeshita, K., Ervin-Haynes, A., Zeldis, J.B. & Vose, J.M. (2009) Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. Journal of Clinical Oncology, 27, 5404–5409.
39. Zein, N., Sinha, A.M., McGahren, W.J. & Ellestad, G.A. (1988) Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240, 1198–1201.